ZURICH, Switzerland, May 18, 2016 /PRNewswire/ --
Haselmeier announces the launch by Merck of their GONAL-f® 2.0prefilled pen following approval by EMA, the European Medicines Agency. Originally launched in 2011 by Merck, a leading science and technology company, the new pen version includes enhancements to further improve the device and bring an increased level
Its enhanced design has made the new GONAL-f® prefilled pen easier to handle with a larger display window that improves the readability of the dosage information. Together with a graduated scale on a transparent cartridge, these new features provide increased clarity for the patient, reassuring them that the correct preset dose has been administered. These enhanced qualities add to the strong original key features of the prefilled pen: dosing accuracy and the ability to improve treatment outcomes by enabling individualized dosing.
Klaus Schmid, Key Account Manager at Haselmeier comments: "We see this as an important next step in the future partnership with Merck to bring technology and life cycle management evolution to the existing portfolio of Merck devices."
And Stefan Gaul, Strategic Product Manager at Haselmeier adds: "We are happy about the opportunity to support Merck with the development of the next generation of GONAL-f® pen design. We are convinced that this new pen will be appreciated by patients, due to its simple and convenient use as well as its sophisticated design."
The GONAL-f® 2.0 prefilled pen is based on Haselmeier's Axis-D pen platform, a disposable multi-use pen with adjustable dosing. Its design is based on an innovative technology featuring a dose window which allows easy dose reading of the adjusted dose and minimizes the risk of incorrect dosing.
Founded in Stuttgart in 1920, Haselmeier is a global medical device company and a leading designer and manufacturer of pen and auto injection systems. The devices feature unique function, design and technology and are marketed by leading pharmaceutical and biotechnology companies around the world. Located in five locations across three continents, we develop and produce innovative technologies for administering medication to improve the health and everyday life of patients.
For more information, please visit http://www.haselmeier.com Media Contact: Haselmeier AG Dufourstrasse 32 8008 Zürich Switzerland Nadia Di Secli Marketing Manager +41-44-250-58-50 email@example.com
SOURCE Haselmeier AG
Subscribe to our Free Newsletters!
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All